Pure Biologics (WAR:PUR) Debt-to-Equity : -4.31 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Pure Biologics Debt-to-Equity?

Pure Biologics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was zł0.11 Mil. Pure Biologics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was zł13.15 Mil. Pure Biologics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was zł-3.08 Mil. Pure Biologics's debt to equity for the quarter that ended in Mar. 2024 was -4.31.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Pure Biologics's Debt-to-Equity or its related term are showing as below:

WAR:PUR' s Debt-to-Equity Range Over the Past 10 Years
Min: -4.31 Med: 0.1 Max: 13.45
Current: -4.31

During the past 8 years, the highest Debt-to-Equity Ratio of Pure Biologics was 13.45. The lowest was -4.31. And the median was 0.10.

WAR:PUR's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs WAR:PUR: -4.31

Pure Biologics Debt-to-Equity Historical Data

The historical data trend for Pure Biologics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pure Biologics Debt-to-Equity Chart

Pure Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.05

-1.73

0.08

0.16

6.84

Pure Biologics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															1.03	2.04	3.18	6.84	-4.31

Competitive Comparison of Pure Biologics's Debt-to-Equity

For the Biotechnology subindustry, Pure Biologics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pure Biologics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pure Biologics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Pure Biologics's Debt-to-Equity falls into.

Pure Biologics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Pure Biologics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.086	+	12.852)	/	1.893
	=	6.83

Pure Biologics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.108	+	13.148)	/	-3.077
	=	-4.31

Pure Biologics (WAR:PUR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Pure Biologics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Pure Biologics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Pure Biologics (WAR:PUR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pure Biologics SA (WAR:PUR) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

PQB:Germany

Address

ul. Dunska 11, Wroclaw, POL, 54-427

Website

http://www.purebiologics.pl

Pure Biologics SA is a Poland based biopharmaceutical company. It invests in the development of new, innovative (non-generic or biosimilar) biological drugs, medical and diagnostic products. It is mainly engaged in the research and development of the biologically active molecule in the drug development process. It specializes in the production and analysis of recombinant proteins and antibodies, contract studies of early product development phases, protein engineering, protein formulation, genomic sequencing, proteomics analysis and bioinformatics. Its projects include cancer immunotherapy, therapy of neurodegenerative diseases, diagnosis of tumors, and other partner projects.

Pure Biologics (WAR:PUR) Headlines

No Headlines